They are going to close this thing below the $125 strike- absolutely nauseating.
Big boys definitely want this thing down by rehashing this one. The defect and problems were made public well over 45 days ago. This sis a timed press release to pound down the stock. Thieving
Yeah, give me names and numbers. I am as picky as anyone and LL have always been straight shooters. I find Tilson reprehensible. This is a real company run in the real world. If you want reasonably priced housing don't make it impossible to do business. I couldn't care less if a split piece of laminate off-gasses or if they buy rare woods from the Russian Mafia. Who made Tilson judge and jury?
You will be kind of hurting considering their testing was done on a "disassembled" piece of flooring in order to skew the results.
CBS has a lot to answer for including who influenced this witch hunt to begin with.
Dream on, I read about the CBS test. I am an architect and have been involved in residential construction for my entire life. CBS is not only skewing the test but they are doing so to influence the test negatively. You have to think in terms of real-world situations and pulling off the backing and planing the material to reach off-gassing uncured glue is absolutely unfair and unrealistic. There are lies and there are damn lies. CBS you are a damn liar.
You would be surprised at how quickly "Len's" attitude could change- all it would take is a health issue on his part and he is at that age. The business model is one thing (stellar), but the execution has been flawless. Every large corporation knows it is hard to catch lightning and REGN has. This company is a target, make no mistake. I always felt it would be Sanofi.
REGN is a $520- $570 stock if a large pharma buys them out. The short traders tried all week and couldn't break it until Friday, which is normally a low volume day. The market makers backed away and the stock price fell. The game is simple- accumulate on these downturns and distribute when the stock resurges. Look for short-term retests of $407 and $437. Remain agnostic unless they introduce a new therapy for a new disease- then look out $700.